Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gosselies – page 9

1 856 clinical trials in Gosselies, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gosselies at a glance
1 856
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 856 trials in Gosselies

Open in trial search

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of BI 764532 with drug combination in patients with extensive‑stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Verastem Inc.

Anaemia

Recruiting

Effect of mitapivat versus placebo on transfusion burden in patients with sickle cell disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:PIPE-791
  • Sponsor:Contineum Therapeutics Inc.

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gosselies

What the registry says about research in the country

01 Immunology Research

Ongoing studies focusing on SARS-CoV-2 immunity patterns in vulnerable populations, particularly examining antibody responses in immunocompromised individuals.

  • Antibody Response Monitoring
  • Variant of Concern Analysis
  • Long-term Immunity Assessment

The research encompasses diverse patient groups including nursing home residents, dialysis patients, and transplant recipients, providing valuable insights into COVID-19 immunity in at-risk populations.

02 Transplant Medicine

Specialized investigation of immune responses in kidney and lung transplant patients, contributing to understanding COVID-19 vulnerability in transplant recipients.

  • Post-transplant Immunity
  • Immunosuppression Impact
  • Patient-specific Response Patterns

This longitudinal study in Belgium aims to enhance protective strategies for transplant recipients during the pandemic.

03 Geriatric Medicine

Comprehensive evaluation of COVID-19 immunity in elderly populations, with special attention to nursing home residents.

  • Age-related Immune Response
  • Elderly Population Protection
  • Long-term Immunity Monitoring

Research focused on understanding immune system responses in older adults to improve prevention strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.